Conatus Pharmaceuticals Inc (NASDAQ:CNAT) traded down 5.5% during mid-day trading on Wednesday . The company traded as low as $6.25 and last traded at $6.54. 891,032 shares traded hands during trading, an increase of 43% from the average session volume of 623,819 shares. The stock had previously closed at $6.92.
A number of equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Conatus Pharmaceuticals in a report on Thursday, March 8th. Zacks Investment Research lowered shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday. Oppenheimer set a $16.00 price objective on shares of Conatus Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, March 7th. ValuEngine raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 2nd. Finally, S&P Equity Research increased their price objective on shares of Conatus Pharmaceuticals from $5.02 to $5.69 in a report on Wednesday, January 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. Conatus Pharmaceuticals currently has an average rating of “Buy” and an average target price of $13.96.
The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.82 and a current ratio of 2.82. The firm has a market capitalization of $196.59, a price-to-earnings ratio of -10.72 and a beta of 1.28.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02. Conatus Pharmaceuticals had a negative net margin of 49.17% and a negative return on equity of 61.58%. The business had revenue of $8.80 million during the quarter, compared to analyst estimates of $9.60 million. research analysts predict that Conatus Pharmaceuticals Inc will post -0.69 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of CNAT. MPM Asset Management LLC grew its holdings in shares of Conatus Pharmaceuticals by 76.3% in the fourth quarter. MPM Asset Management LLC now owns 2,101,171 shares of the biotechnology company’s stock valued at $9,707,000 after purchasing an additional 909,091 shares in the last quarter. State Street Corp purchased a new position in shares of Conatus Pharmaceuticals in the second quarter valued at $2,092,000. Northern Trust Corp grew its holdings in shares of Conatus Pharmaceuticals by 640.6% in the second quarter. Northern Trust Corp now owns 297,152 shares of the biotechnology company’s stock valued at $1,712,000 after purchasing an additional 257,030 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Conatus Pharmaceuticals by 31.2% in the second quarter. Vanguard Group Inc. now owns 1,006,890 shares of the biotechnology company’s stock valued at $5,800,000 after purchasing an additional 239,373 shares in the last quarter. Finally, Sterling Capital Management LLC purchased a new position in shares of Conatus Pharmaceuticals in the third quarter valued at $708,000. 39.57% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://ledgergazette.com/2018/03/14/conatus-pharmaceuticals-cnat-shares-down-5-5.html.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.